{"id":"3ee0302c-a69a-5c2f-9a85-f64f568231aa","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-cyp2a13-luteolin","predicate":"reported_relationship","statement":"Recombinant human CYP2A13 converted apigenin to luteolin, with reported substrate S50 of 14 micromolar.","claim_class":"mechanistic","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"5037dec2-d7ea-5898-8d28-fcd52f1a818a","mechanism_event_label":"Recombinant human CYP2A13 converted apigenin to luteolin, with reported substrate S50 of 14 micromolar.","subject":{"id":"56cb4616-8555-596a-a9ab-b3ca031692b1","slug":"cyp2a13","display_name":"Human cytochrome P450 2A13 / CYP2A13","entity_type_key":"protein"},"object":{"id":"80472c4b-ecc2-52e3-a766-f8463294774f","slug":"luteolin","display_name":"Luteolin / 3′,4′,5,7-tetrahydroxyflavone","entity_type_key":"small_molecule"},"evidence_count":1,"mechanism_event":{"id":"5037dec2-d7ea-5898-8d28-fcd52f1a818a","stable_key":"ff370329-68a3-573d-96ee-597de78a3967:api-cyp2a13-luteolin-event","event_type":"biochemical_relationship","label":"Recombinant human CYP2A13 converted apigenin to luteolin, with reported substrate S50 of 14 micromolar.","description":"### api-cyp2a13-luteolin\n\nRecombinant human CYP2A13 converted apigenin to luteolin, with reported substrate S50 of 14 micromolar.\n\nModel and exposure: Recombinant human enzyme; not whole-body metabolic flux.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Oxidation of Naringenin, Apigenin, and Genistein by Human Family 1 Cytochrome P450 Enzymes and Comparison of Interaction of Apigenin with Human P450 1B1.1 and Scutellaria P450 82D.1. | 2023 | https://pubmed.ncbi.nlm.nih.gov/37783573/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11497155/ | https://doi.org/10.1021/acs.chemrestox.3c00229 | Access: Indexed primary abstract and publisher-indexed Results; recombinant-enzyme selectivity, not complete human metabolic mass balance.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"4425961f-4764-56d3-9887-87e47749379b","slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"},"role":"substrate","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"56cb4616-8555-596a-a9ab-b3ca031692b1","slug":"cyp2a13","display_name":"Human cytochrome P450 2A13 / CYP2A13","entity_type_key":"protein"},"role":"catalyst","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"80472c4b-ecc2-52e3-a766-f8463294774f","slug":"luteolin","display_name":"Luteolin / 3′,4′,5,7-tetrahydroxyflavone","entity_type_key":"small_molecule"},"role":"product","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_access","value_text":"Indexed primary abstract and publisher-indexed Results; recombinant-enzyme selectivity, not complete human metabolic mass balance.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Recombinant human enzyme; not whole-body metabolic flux.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Recorded from source with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Apigenin collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"apigenin","display_name":"Apigenin","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Recombinant human CYP2A13 converted apigenin to luteolin, with reported substrate S50 of 14 micromolar.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Oxidation of Naringenin, Apigenin, and Genistein by Human Family 1 Cytochrome P450 Enzymes and Comparison of Interaction of Apigenin with Human P450 1B1.1 and Scutellaria P450 82D.1. | https://pubmed.ncbi.nlm.nih.gov/37783573/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11497155/ | https://doi.org/10.1021/acs.chemrestox.3c00229","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference api-cyp2a13-luteolin; ","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"ba3487e3-d1e7-53a2-a98f-b75780149462","evidence_kind":"source_excerpt","locator":"Lines 106-112","start_line":106,"end_line":112,"excerpt":"### api-cyp2a13-luteolin\n\nRecombinant human CYP2A13 converted apigenin to luteolin, with reported substrate S50 of 14 micromolar.\n\nModel and exposure: Recombinant human enzyme; not whole-body metabolic flux.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: Oxidation of Naringenin, Apigenin, and Genistein by Human Family 1 Cytochrome P450 Enzymes and Comparison of Interaction of Apigenin with Human P450 1B1.1 and Scutellaria P450 82D.1. | 2023 | https://pubmed.ncbi.nlm.nih.gov/37783573/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC11497155/ | https://doi.org/10.1021/acs.chemrestox.3c00229 | Access: Indexed primary abstract and publisher-indexed Results; recombinant-enzyme selectivity, not complete human metabolic mass balance.","model_system":"Recombinant human enzyme; not whole-body metabolic flux.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"54eac90b-add1-5f56-9036-d900307c5697","stable_key":"import-ff370329-68a3-573d-96ee-597de78a3967","title":"Apigenin: detailed mechanisms of action (reviewed 10 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed.","file_path":"","sha256":"ede6e5c6b91d66b66844f2ff667a7f8303d9ac1281f15dc09db703f7de4da942","revision_id":"b41a39a2-0197-549c-97a5-1765e6696931","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}